A Leader in the Discovery and Development of Small Molecules that Disrupt Protein-Protein Interactions

Ascentage Pharma is a globally-focused, clinical-stage biotechnology company developing novel therapies for cancers, hepatitis B virus and age-related diseases. Our expertise is in developing inhibitors of protein-protein interactions (PPIs) to restore apoptosis, or programmed cell death. We have eight drug candidates in Phase I or II clinical trials in the U.S., Australia and China, including a novel Bcl-2/Bcl-xL inhibitor as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs).

Learn More

Targeting Key Regulatory Proteins
in Apoptotic Pathways




Global Clinical Trials

Learn More

San Antonio, TX

San Diego, CA

Rochester, MN

Ann Arbor, MI

Cleveland, OH

Philadelphia, PA

Baltimore, MD




Nedlands, AU

Camperdown, AU